Seelos Therapeutics Inc (SEEL)

[mean gene]

I do not know why all the fuss about managements receiving restricted stock and options grants is all about. The restricted stock do not vest until 2-15-17 and the options have a four year vesting period. The options have an exercise price of $1.11, if this is such a steal at shareholders expense then we have a better offer now than management, we can buy all we want at $1.06. Sarissa has to pay $.88 for their warrants and what they have already purchased is higher than the recent $.78 low price. In this economic environment it is probably difficult to obtain financing even for companies with positive cash flow and I would imagine for a small bio-tech company would be very challenging. The fact the Sarissa and Aspire are investing for the long term is very encouraging. I am not pumping this stock, I own an amount than is of institutional size and my average price is $3.42 and I believe I will gain a profit on this investment.